

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon-Bopal
Road, Ambli, Ahmedabad, Gujarat - 380058
compliance@arveelabs.com CIN: L24231GJ2012PLC068778
www.arveelabs.com, Tel: 91- 2717-430479

=====

Date: 12TH August, 2025

**To,
National Stock Exchange of India
Mumbai**

Scrip Code: ARVEE

ISIN: INE006Z01016

Sub: Outcome of Board Meeting held on 12th August, 2025

Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 the meeting of the Board of Directors held today amongst others interalia approved the following matters:

- a) Results for the quarter ended on 30th June, 2025.
- b) Limited Review Report for the period ended on 30th June, 2025.
- c) Appointment of Mr. Saurin Ajitbhai Gandhi as an Additional Director of the Company.
- d) Approved the Directors Report together with its attachments.
- e) Appointed Mr. Alkesh Jalan as a Scrutiniser for the Annual General Meeting for the year ended on 31st March, 2025.
- f) Approved the date of Annual General Meeting to be held on Wednesday, 24th September, 2025.
- g) Approved the Book closure dates from Saturday, 20th September, 2025 to Wednesday, 24th September, 2025 for the purpose of annual general meeting.

The requisite details in respect of appointment of Mr. Saurin Ajitbhai Gandhi is attached herewith as Annexure A.

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon-Bopal
Road, Ambli, Ahmedabad, Gujarat - 380058

compliance@arveelabs.com CIN: L24231GJ2012PLC068778

www.arveelabs.com, Tel: 91- 2717-430479

=====

The Board Meeting started at 15.00 Hours and concluded at 16.20 Hours.

Kindly take the above information on record.

Thanking You,

For, Arvee Laboratories (India) Limited

Company Secretary and Compliance Officer

Raina Singh

A 57624

ARVEE LABORATORIES (INDIA) LIMITED

Registered Address: 403, Entice, Nr. Jayantilal Park BRTS, Iskcon-Bopal
Road, Ambli, Ahmedabad, Gujarat - 380058
compliance@arveelabs.com CIN: L24231GJ2012PLC068778
www.arveelabs.com, Tel: 91- 2717-430479

=====

Annexure A

Appointment of Mr. Saurin Ajitbhai Gandhi (DIN: 11237690) as an Additional Director of the Company.

1	Reason for change of appointment / Resignation	Appointment
2	Date of appointment	12 th August, 2025
3	Brief Profile in case of appointment	Mr. Saurin Ajit Gandhi, aged 42 years, holds Master's degree in Commerce with main subject of Accounts and Finance from Gujarat University, Ahmedabad. He has vast experience of 15 years and in-depth knowledge of the Accounts, Finance, Company's Liasioning work etc. He is also currently acting as Chief Financial officer of the Company.
4	Relation with Directors of the Company (in case of appointment)	Nil
5	Shareholding in the Company	4000 Equity Shares

Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.



Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.

**ARVEE LABORATORIES (INDIA) LIMITED****CIN: L24231GJ2012PLC068778****Registered Office: 403, Entice, Nr. Jayantilal Park BRTS,
Iskcon Bopal Road, Ambli, Ahmedabad - 380058****Tel : +91 – 2717-430479 || +91 – 2717-410819; Website : www.arveelabs.com; Email ID : compliance@arveelabs.com****STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30, 2025****(₹ in Lakhs, except per share data)**

Sr. No.	Particulars	Quarter ended		Year ended	
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Un-Audited	Audited	Un-Audited	Audited
1	Revenue from Operations	748.00	645.00	1,060.22	3,848.72
2	Other Income	16.87	20.81	10.64	65.73
3	Total Revenue (1+2)	764.87	665.80	1,070.86	3,914.45
4	Expenses				
	Cost of material consumed	548.27	254.72	430.82	1,887.29
	Changes in inventories of finished goods, work-in-progress and stock in trade	(206.34)	(24.40)	183.21	180.74
	Employee benefit Expenses	167.59	114.91	106.39	449.47
	Finance Costs	4.33	6.99	7.79	24.87
	Depreciation and amortisation expenses	29.41	26.83	30.66	114.88
	Other expenses	204.19	277.39	186.09	970.10
	Total Expenses (4)	747.45	656.43	944.96	3,627.36
5	Profit / (Loss) before exceptional items and tax (1-4)	17.42	9.37	125.90	287.09
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5-6)	17.42	9.37	125.90	287.09
8	Tax expense				
	Current Tax	0.51	(11.50)	31.69	58.40
	Deferred Tax	-	13.96	-	13.96
9	Profit / (Loss) for the period from continuing operations (7-8)	16.91	6.92	94.21	214.74
10	Profit / (Loss) from discontinued operations	-	-	-	-
11	Tax Expense of discontinued operations	-	-	-	-
12	Profit / (Loss) from discontinued operations (after tax) (10-11)	-	-	-	-
13	Profit / (Loss) for the period (9+12)	16.91	6.92	94.21	214.74
14	Other Comprehensive Income				
	a. Items that will not be reclassified to profit or loss (Net of tax)	-	-	-	-
	b. Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-
15	Total Comprehensive Income for the period (13+14)	16.91	6.92	94.21	214.74
	Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	1102.00	1102.00	1102.00	1102.00



Arvee Laboratories (India) Limited.

Formerly known as Arvee Laboratories (India) Pvt. Ltd.

403, Entice Building, Opposite Jayantilal Park BRTS Bus Stop,
Iskcon – Bopal Road, Ambli, Ahmedabad 380 058, Gujarat, India.

Phone: +91- 2717-430479 | +91- 2717-410819

e-mail: info@arveelabs.com, Website: www.arveelabs.com

CIN No. :- L24231GJ2012PLC068778.



Sr. No.	Particulars	Quarter ended			Year ended
		30/06/2025	31/03/2025	30/06/2024	31/03/2025
		Un-Audited	Audited	Un-Audited	Audited
16	Earnings per equity share (for continuing operation)				
	Basic	0.15	0.06	0.85	1.95
	Diluted	0.15	0.06	0.85	1.95
17	Earnings per equity share (for discontinued operation)				
	Basic	-	-	-	-
	Diluted	-	-	-	-
18	Earnings per equity share (for continuing & discontinued operation)				
	Basic	0.15	0.06	0.85	1.95
	Diluted	0.15	0.06	0.85	1.95
	Paid-up equity share capital (Face value of ₹ 10 each)	1,102.00	1,102.00	1,102.00	1,102.00
	Other Equity excluding Revaluation Reserve	2,041.05	2,024.13	1,903.61	2,024.13

Notes :



- 1 The aforesaid Financial Results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at its Meeting held on Tuesday, August 12, 2025. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2 The aforesaid Financial Results for the quarter ended June 30, 2025 have been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation- 33 and Regulation- 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 In line with Ind AS - 108 Operating Segments and basis of the review of operations being done by the Senior Management, the operations of the Company fall under the Chemicals business which is considered to be the only reportable segment by the management.
- 4 Figures for the quarter ended on 30th June, 2025 and Year ended on 31st March, 2025 the Company has adopted Ind AS. The adoption of the standard did not have any material impact to the financial statements of the Company.
- 5 The figures for the corresponding Previous period have been restated / regrouped wherever necessary, to make them comparable.

For and on behalf of Board of Directors of
ARVEE LABORATORIES (INDIA) LIMITED

SHALIN SUDHAKARBHAI PATEL
CHAIRMAN CUM MANAGING DIRECTOR
DIN: 01779902

Date: August 12, 2025

Place: Ahmedabad



INDEPENDENT AUDITOR'S REPORT

To,
THE BOARD OF DIRECTORS OF
ARVEE LABORATORIES (INDIA) LIMITED
AHMEDABAD

Independent Auditors Review Report on Standalone Unaudited Financial Results of the Arvee Laboratories (India) Limited pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of ARVEE LABORATORIES (INDIA) LIMITED ("the Company") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Nirav Patel & Associates
Chartered Accountants
(Firm's Registration No. 129824W)

CA Nirav Patel
Partner
(Membership No. 132409)
UDIN: 25132409BMLKQP8523



Place: Ahmedabad
Date: August 12, 2025